PMID- 34045876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 14
DP  - 2021
TI  - Roux-en-Y Gastric Bypass Improves Hepatic Glucose Metabolism Involving 
      Upregulation of Sirt1 in Type 2 Diabetes Mellitus.
PG  - 2269-2280
LID - 10.2147/DMSO.S298897 [doi]
AB  - BACKGROUND: Roux-en-Y gastric bypass (RYGB) is the most effective treatment for 
      type 2 diabetes mellitus (T2DM). Previous studies have reported that silent 
      information regulator 1 (Sirt1) closely relates to many pathological processes of 
      glucose metabolism and insulin resistance (IR). However, it is unclear whether 
      Sirt1 is involved in the hepatic glucose metabolism of T2DM after RYGB. METHODS: 
      T2DM rats were randomly divided into four groups: Control, DM, Diet and RYGB. 
      Normal rats were served as the control group. Hematoxylin and eosin (H&E) 
      staining and Masson staining assays were performed to explore the changes of 
      liver fibrous tissue after RYGB. The effect of RYGB on the protein expression of 
      Sirt1 was detected by the Western blotting assay and immunohistochemical assay. 
      Next, we built the insulin resistance model of human hepatocyte cell lines 
      (FL62891 and HHL5) using the human recombinant insulin. Western blotting assay 
      was applied to determine the expression of Sirt1 and the expression change of 
      IRS1/mTOR2 /PKB pathway-related proteins in FL62891 and HHL5 cells. Additionally, 
      the effects of Sirt1 on the expression of PTP1B and FGF-21 in insulin-resistant 
      FL62891 and HHL5 cells were investigated using Western blotting and 
      immunofluorescence assay. RESULTS: Our results showed that following RYGB 
      improved the pathological changes of liver and increased the expression of Sirt1 
      in rats with T2DM compared with the diabetic rats. In experiments in vitro, the 
      expression of Sirt1 was downregulated in insulin-resistance FL62891 and HHL5 
      cells. Moreover, overexpression of Sirt1 significantly increased the expression 
      of FGF-21 whereas decreased the expression of PTP1B in insulin-resistance FL62891 
      and HHL5 cells. These above changes were alleviated in RYGB and Diet groups. 
      Furthermore, RYGB could improve the glucose metabolism through activating 
      IRS1/mTOR2/PKB pathways by regulating Sirt1 in rats with T2DM. CONCLUSION: RYGB 
      could significantly improve hepatic glucose metabolism and increase the 
      expression of Sirt1 in T2DM rats, which is related to the IRS1/mTOR2 /PKB 
      pathway.
CI  - (c) 2021 Su et al.
FAU - Su, Chunjie
AU  - Su C
AD  - Department of Gastrointestinal Surgery, Jingmen No.1 People's Hospital, Jingmen, 
      448000, People's Republic of China.
FAU - Cheng, Qian
AU  - Cheng Q
AD  - Department of Endocrinology, Yixing People's Hospital, Yixing, 214200, Jiangsu, 
      People's Republic of China.
FAU - Wang, Liyun
AU  - Wang L
AD  - Department of Endocrinology, Yixing People's Hospital, Yixing, 214200, Jiangsu, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210520
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC8145911
OTO - NOTNLM
OT  - IRS1
OT  - PKB
OT  - RYGB
OT  - Roux-en-Y gastric bypass
OT  - Sirt1
OT  - hepatic glucose metabolism
OT  - insulin resistance
OT  - mTOR2
COIS- The authors declare that they have no conflicts of interest for this work.
EDAT- 2021/05/29 06:00
MHDA- 2021/05/29 06:01
PMCR- 2021/05/20
CRDT- 2021/05/28 07:21
PHST- 2020/12/23 00:00 [received]
PHST- 2021/03/25 00:00 [accepted]
PHST- 2021/05/28 07:21 [entrez]
PHST- 2021/05/29 06:00 [pubmed]
PHST- 2021/05/29 06:01 [medline]
PHST- 2021/05/20 00:00 [pmc-release]
AID - 298897 [pii]
AID - 10.2147/DMSO.S298897 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2021 May 20;14:2269-2280. doi: 10.2147/DMSO.S298897. 
      eCollection 2021.